1 |
Heise, C. E., Santos, W. L., Schreihofer, A. M., Heasley, B. H., Mukhin, Y. V., Macdonald, T. L. and Lynch, K. R. (2001) Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a receptor antagonist. Mol. Pharmacol. 60, 1173-1180.
DOI
|
2 |
Im, D. S. (2010) Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol. Sin. 31, 1213-1222.
DOI
|
3 |
Leclerc, C., Neant, I. and Moreau, M. (2012) The calcium: an early signal that initiates the formation of the nervous system during embryogenesis. Front. Mol. Neurosci. 5, 3.
|
4 |
Lee, J. M., Park, S. J. and Im, D. S. (2015) Lysophosphatidylethanolamine increases intracellular through in PC-12 neuronal cells. Biochem. Biophys. Res. Commun. 461, 378-382.
DOI
|
5 |
Makide, K., Kitamura, H., Sato, Y., Okutani, M. and Aoki, J. (2009) Emerging lysophospholipid mediators, lysophosphatidylserine, lyso-phosphatidylthreonine, lysophosphatidylethanolamine and lysophospha-tidylglycerol. Prostaglandins Other Lipid Mediat. 89, 135-139.
DOI
|
6 |
Melchior, B. and Frangos, J. A. (2012) Gaq/11-mediated intracellular calcium responses to retrograde flow in endothelial cells. Am. J. Physiol. Cell Physiol. 303, C467-C473.
DOI
|
7 |
Meylaers, K., Clynen, E., Daloze, D., DeLoof, A. and Schoofs, L. (2004) Identification of 1-lysophosphatidylethanolamine (C(16:1)) as an antimicrobial compound in the housefly, Musca domestica. Insect Biochem. Mol. Biol. 34, 43-49.
DOI
|
8 |
Misra, U. K. (1965) Isolation of lysophosphatidylethanolamine from human serum. Biochim. Biophys. Acta 106, 371-378.
DOI
|
9 |
Ohta, H., Sato, K., Murata, N., Damirin, A., Malchinkhuu, E., Kon, J., Kimura, T., Tobo, M., Yamazaki, Y., Watanabe, T., Yagi, M., Sato, M., Suzuki, R., Murooka, H., Sakai, T., Nishitoba, T., Im, D. S., Nochi, H., Tamoto, K., Tomura, H. and Okajima, F. (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64, 994-1005.
DOI
|
10 |
Nishina, A., Kimura, H., Sekiguchi, A., Fukumoto, R. H., Nakajima, S. and Furukawa, S. (2006) Lysophosphatidylethanolamine in Grifola frondosa as a neurotrophic activator via activation of MAPK. J. Lipid Res. 47, 1434-1443.
DOI
|
11 |
Park, K. S., Kim, M. K., Im, D. S. and Bae, Y. S. (2007a) Effect of lysophosphatidylglycerol on several signaling molecules in OVCAR-3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor. Biochem. Pharmacol. 73, 675-681.
DOI
|
12 |
Park, K. S., Lee, H. Y., Lee, S. Y., Kim, M. K., Kim, S. D., Kim, J. M., Yun, J., Im, D. S. and Bae, Y. S. (2007b) Lysophosphatidylethanolamine stimulates chemotactic migration and cellular invasion in SK-OV3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor. FEBS Lett. 581, 4411-4416.
DOI
|
13 |
Young, K. W., Challiss, R. A., Nahorski, S. R. and MacKrill, J. J. (1999) Lysophosphatidic acid-mediated mobilization in human SHSY5Y neuroblastoma cells is independent of phosphoinositide signalling, but dependent on sphingosine kinase activation. Biochem. J. 343 Pt 1, 45-52.
DOI
|
14 |
Park, S. J., Lee, K. P. and Im, D. S. (2014a) Action and Signaling of Lysophosphatidylethanolamine in MDA-MB-231 Breast Cancer Cells. Biomol. Ther. (Seoul) 22, 129-135.
DOI
|
15 |
Park, S. J., Lee, K. P., Kang, S., Chung, H. Y., Bae, Y. S., Okajima, F. and Im, D. S. (2013) Lysophosphatidylethanolamine utilizes and CD97 in MDA-MB-231 breast cancer cells. Cell. Signal. 25, 2147-2154.
DOI
|
16 |
Park, S. J., Lee, K. P., Kang, S., Lee, J., Sato, K., Chung, H. Y., Okajima, F. and Im, D. S. (2014b) Sphingosine 1-phosphate induced anti-atherogenic and atheroprotective M2 macrophage polarization through IL-4. Cell. Signal. 26, 2249-2258.
DOI
|
17 |
Swaney, J. S., Chapman, C., Correa, L. D., Stebbins, K. J., Broadhead, A. R., Bain, G., Santini, A. M., Darlington, J., King, C. D., Baccei, C. S., Lee, C., Parr, T. A., Roppe, J. R., Seiders, T. J., Ziff, J., Prasit, P., Hutchinson, J. H., Evans, J. F. and Lorrain, D. S. (2011) Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J. Pharmacol. Exp. Ther. 336, 693-700.
DOI
|
18 |
Castelino, F. V., Seiders, J., Bain, G., Brooks, S. F., King, C. D., Swaney, J. S., Lorrain, D. S., Chun, J., Luster, A. D. and Tager, A. M. (2011) Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum. 63, 1405-1415.
DOI
|
19 |
Choi, J. W. and Chun, J. (2013) Lysophospholipids and their receptors in the central nervous system. Biochim. Biophys. Acta 1831, 20-32.
DOI
|
20 |
Young, K. W., Bootman, M. D., Channing, D. R., Lipp, P., Maycox, P. R., Meakin, J., Challiss, R. A. and Nahorski, S. R. (2000) Lysophosphatidic acid-induced mobilization requires intracellular sphingosine 1-phosphate production. Potential involvement of endogenous EDG-4 receptors. J. Biol. Chem. 275, 38532-38539.
DOI
|
21 |
Zhang, Y., Chen, Y. C., Krummel, M. F. and Rosen, S. D. (2012) Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells. J. Immunol. 189, 3914-3924.
DOI
|
22 |
Cowan, A. K. (2009) Plant growth promotion by 18:0-lyso-phosphatidylethanolamine involves senescence delay. Plant Signal. Behav. 4, 324-327.
DOI
|